Hematology News

Interest in transthyretin cardiac amyloidosis, or ATTR-CM, has grown in part due to three areas of recent advancement: imaging, recognition of the lesser-known disease and drug approvals.

Taimur Sher, MBBS, MD a hematologist, internist and oncologist at the Mayo Clinic Cancer Center who leads the Multispecialty Amyloidosis Clinic at Mayo Clinic in Jacksonville, Florida, spoke with Healio about how to recognize and diagnose transthyretin amyloidosis, the newest FDA-approved treatments and the importance of genetic counseling in disease management.

A case series published in Circulation by physicians at Lille University Hospital in France reported twice the prevalence of pulmonary embolism among patients with COVID-19 admitted to the ICU compared with patients admitted to the ICU the same time in 2019.

ASH and ASCO launched data registries to capture important insights and guide patient care during and beyond the COVID-19 pandemic.

Patients treated with PCSK9 inhibitors had reduced risk for venous thromboembolism, especially if they had elevated lipoprotein(a), according to findings presented at the virtual American College of Cardiology Scientific Session.

CytoSorbents Corp. announced that its blood purification technology for the treatment of deadly inflammation and cytokine storm has been granted Emergency Use Authorization by the FDA for patients with COVID-19.

For Allison A. King, MD, MPH, PhD, a recent study of junior hematologists who attended ASH’s mentored research training program yielded largely positive results.

The FDA approved luspatercept-aamt to treat anemia among certain adults with lower-risk myelodysplastic syndrome.

Global Blood Therapeutics committed $250,000 to support the sickle cell disease community during the COVID-19 pandemic.

The FDA has revised its deferral policy for blood donations by men who have sex with men and their partners, as well as individuals with tattoos and piercings and other groups, in order to help maintain the blood supply during the , according to a statement from the agency.